Pharma Deals Review, Vol 2008, No 99 (2008)

Font Size:  Small  Medium  Large

Negotiations Begin Between Bristol-Myers Squibb and ImClone

Taskin Ahmed

Abstract


Bristol-Myers Squibb has offered to buy the remaining shares of ImClone for US$4.3B in cash. If the deal is successful, not only will it launch Bristol-Myers Squibb back into oncology since its loss of Taxol® to generic competition in 2001, but could also make the company ripe for acquisition itself.

Full Text: pdf html

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.